Abstract
Overall survival of patients suffering from upper gastrointestinal (GI) cancer is still poor. Most of the patients are diagnosed in advanced stages. But even in patients with operable disease, the recurrence rates, especially of gastric and pancreatic neoplasias, are still very high. Much effort has therefore been put in the development of palliative and curative therapeutic concepts. The aim of this article is to summarize the most important publications presented at American Society of Clinical Oncology (ASCO) 2013 concerning gastric and pancreatic cancer with the main focus on relevance for clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol. 2013;31 (Suppl; abstr 4008).
Von Hoff DD, Ervin ThJ, Arena FP, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol. 2013;31 (Suppl; abstr 4005).
Rivera F, Jiménez P, Alfonso PG, et al. NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis. J Clin Oncol. 2013;31 (Suppl; abstr 4098).
Yoshida K, Tsuburaya A, Kobayashi M, et al. SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. J Clin Oncol. 2013;31 (Suppl; abstr LBA4002).
Hecht RJ, Bang Y-J, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC trial. J Clin Oncol. 2013;31 (Suppl; abstr LBA4001).
Thuss-Patience PC, Kretzschmar A, Bichev D. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306–14.
Cook N, Marshall A, Blazeby JM, et al. Cougar-02: a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. J Clin Oncol. 2013;31 (Suppl; abstr 4023).
Fuchs CS, Tomasek J, Cho JY, et al. REGARD: a phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. J Clin Oncol. 2012; 30 (Suppl 34; abstr LBA5).
Conflict of interest
The authors declare that there are no actual or potential conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wöll, E. Upper gastrointestinal cancer: POST ASCO 2013. memo 6, 220–221 (2013). https://doi.org/10.1007/s12254-013-0105-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-013-0105-9